In a nutshell This article looked at the effectiveness of gefitinib (Iressa) combined with chemotherapy when compared to a chemotherapy aline in the treatment of non-small cell lung cancer (NSCLC). The authors found that the addition of gefitinib to a chemotherapy increased the progression-free survival (PFS) of these...
Read More
In a nutshell This trial is aiming to examine the effectiveness of ipatasertib in combination with atezolizumab (Tecentriq) and paclitaxel (Taxol) for the treatment of advanced triple-negative breast cancer (TNBC) that cannot be surgically removed. The main outcomes to be measured in this trial is survival without progression of the disease and...
Read More
In a nutshell This trial is aiming to examine the effectiveness and safety of atezolizumab (Tecentriq) and tiragolumab compared to durvalumab (Imfinzi) in stage III non-small-cell lung cancer (NSCLC) that cannot be surgically removed and has previously been treated with concurrent (at the same time) platinum-based chemoradiation therapy (CRT)....
Read More
In a nutshell This study investigated the differences in following the guidelines for advanced rectal cancer treatments. Researchers suggested chemotherapy after the complete removal of rectal cancer improves survival. Some background This year, an estimated 147,950 adults in the US will be diagnosed with colorectal cancer. Of these, 43,340 will be...
Read More
In a nutshell This study is looking to examine the effectiveness of durvalumab (Imfinzi) and consolidation stereotactic body radiation therapy (SBRT) after chemoradiation for locally advanced stage III non-small-cell lung cancer (NSCLC). The main outcomes to be measured are the occurrence of side effects and the survival without cancer...
Read More
In a nutshell This phase 2 trial will investigate the safety of experimental treatment zanidatamab (ZW25) in combination with palbociclib (Ibrance) and fulvestrant (Faslodex) in patients with advanced breast cancer (BC). The main outcomes evaluated will be the rate of side effects and survival without cancer worsening. This trial is...
Read More
In a nutshell This study was carried out to determine whether combination therapy with a standard-dose pembrolizumab (Keytruda) plus reduced-dose ipilimumab (Yervoy) could be used as a treatment option in patients with advanced melanoma. The study found that this combination had good outcomes and manageable side effects in...
Read More
In a nutshell This study evaluated whether the safety and effectiveness of iodine (I)-seeded brachytherapy (IBT) for the treatment of NSCLC in older people. The study found that CT-guided IBT is an effective and safe therapy and can be considered as an alternative to surgery and radiotherapy for elderly patients with NSCLC. Some background...
Read More
In a nutshell The study monitored the occurrence of possible immune-related side effects (irSEs) in patients with advanced melanoma under single and combination therapy of ipilimumab (I; Yervoy), nivolumab (N; Opdivo), and pembrolizumab (P; Keytruda). The authors found that combination therapy increases the frequency of irSEs. Some background...
Read More
In a nutshell The study assessed whether pembrolizumab (Keytruda) could be used in addition to neoadjuvant chemotherapy (NAC; chemotherapy before surgery) to improve the outcomes of patients with early triple-negative breast cancer (TNBC). The study found that more patients treated with pembrolizumab had a complete response. Some...
Read More
In a nutshell This study compared the effectiveness and safety of two different chemotherapies in the treatment of advanced colorectal cancer (CRC). Researchers suggested that S1-based chemotherapy is a good option for the treatment of these patients. Some background CRC is one of the most common cancers worldwide. The standard treatment is surgery...
Read MoreIn a nutshell This study set out to compare conventional-dose chemoradiotherapy (CRT) to reduced CRT based on 18F-FDG PET in locally advanced non-small cell lung cancer (NSCLC). The investigators found that 18F-FDG PET-based CRT improved tumor control without increasing side effects in these patients. Some background NSCLC accounts for...
Read More
